Clinical Trial Update: IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports on a Phase 1 study evaluating a three-drug combination of IRX-2, cyclophosphamide, and nivolumab in patients with recurrent, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• IRX-2
• nivolumab (nivolumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING